SDS

7
Symptoms related to the physical, chemical and toxicological characteristics: Pharyngitis,
epistaxis, flu syndrome, cough increased, bronchitis, dyspepsia, tooth disorder, headache,
pharyngolaryngeal pain, nasopharyngitis, abdominal upper pain, diarrhea, and excoriation.
Effects of short-term (acute) exposure: Harmful if swallowed.
Effects of long-term (chronic) exposure: Causes damage to organs (endocrine system) through
prolonged or repeated exposure. In addition, nasal corticosteroids have been associated with nasal
septal perforation, glaucoma and cataracts, and impaired wound healing.
Acute toxicity (LD50):
Oral route, rat: 1,451 mg/kg.
Oral route, mouse: 2,168 mg/kg.
Skin corrosion/irritation: Not a skin irritant in animal studies.
Serious eye damage/irritation: Transient eye irritant in animal studies.
Sensitization: Non-sensitizing based on animal studies.
Specific target organ toxicity – single exposure (STOT-SE): No data available.
Specific target organ toxicity – repeated exposure (STOT-RE): Causes damage to organs
(endocrine system) through prolonged or repeated exposure.
Carcinogenicity: In a two-year study in rats, triamcinolone acetonide caused no treatment-related
carcinogenicity at oral doses up to 1.0 mcg/kg (less than the maximum recommended daily
intranasal dose in adults and children on a mcg/m
2
basis, respectively). In a two-year study in
mice, triamcinolone acetonide caused no treatment-related carcinogenicity at oral doses up to 3.0
mcg/kg (less than the maximum recommended daily intranasal dose in adults and children on a
mcg/m
2
basis, respectively).
Not listed by NTP, not found to be a potential carcinogen by IARC or OSHA.
Reproductive toxicity and teratogenicity: Triamcinolone acetonide was teratogenic in rats,
rabbits, and monkeys. Experience with oral corticosteroids in pharmacologic as opposed to
physiologic doses suggests that rodents are more prone to teratogenic effects from corticosteroids
than humans.
In reproduction studies in rats and rabbits, triamcinolone acetonide administered by inhalation
produced cleft palate and/or internal hydrocephaly and axial skeletal defects at exposures less
than and 2 times, respectively, the maximum recommended daily intranasal dose in adults on a
mcg/m
2
basis. In a monkey reproduction study, triamcinolone acetonide administered by
inhalation produced cranial malformations at an exposure approximately 37 times the maximum
recommended daily intranasal dose in adults on a mcg/m
2
basis.
Mutagenicity: No evidence of mutagenicity was detected from in vitro tests (a reverse mutation
test in Salmonella bacteria and a forward mutation test in Chinese hamster ovary cells) conducted
with triamcinolone acetonide.
Aspiration hazard: No data available.